278 related articles for article (PubMed ID: 24942741)
1. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.
Zhao K; Li S; Wu L; Lai C; Yang G
J Biol Chem; 2014 Jul; 289(30):20824-35. PubMed ID: 24942741
[TBL] [Abstract][Full Text] [Related]
2. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
3. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
4. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
5. Stromal TGF-β signaling induces AR activation in prostate cancer.
Yang F; Chen Y; Shen T; Guo D; Dakhova O; Ittmann MM; Creighton CJ; Zhang Y; Dang TD; Rowley DR
Oncotarget; 2014 Nov; 5(21):10854-69. PubMed ID: 25333263
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
7. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
Nakka M; Agoulnik IU; Weigel NL
Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
[TBL] [Abstract][Full Text] [Related]
10. The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.
Siddiqui S; Libertini SJ; Lucas CA; Lombard AP; Baek HB; Nakagawa RM; Nishida KS; Steele TM; Melgoza FU; Borowsky AD; Durbin-Johnson BP; Qi L; Ghosh PM; Mudryj M
Cancer Lett; 2020 Jul; 483():12-21. PubMed ID: 32330514
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
12. ARF represses androgen receptor transactivation in prostate cancer.
Lu W; Xie Y; Ma Y; Matusik RJ; Chen Z
Mol Endocrinol; 2013 Apr; 27(4):635-48. PubMed ID: 23449888
[TBL] [Abstract][Full Text] [Related]
13. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
[TBL] [Abstract][Full Text] [Related]
14. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
15. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
16. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
17. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.
Zhu W; Zhang JS; Young CY
Carcinogenesis; 2001 Sep; 22(9):1399-403. PubMed ID: 11532861
[TBL] [Abstract][Full Text] [Related]
18. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
19. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.
Sun F; Indran IR; Zhang ZW; Tan MH; Li Y; Lim ZL; Hua R; Yang C; Soon FF; Li J; Xu HE; Cheung E; Yong EL
Carcinogenesis; 2015 Jul; 36(7):757-68. PubMed ID: 25908644
[TBL] [Abstract][Full Text] [Related]
20. Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.
Zimmer BM; Howell ME; Wei Q; Ma L; Romsdahl T; Loughman EG; Markham JE; Seravalli J; Barycki JJ; Simpson MA
Horm Cancer; 2016 Aug; 7(4):260-71. PubMed ID: 27307252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
